← All trials
NCT05411237
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2022
- Primary completion
- Dec 31, 2027
- Completion date
- Sep 30, 2028
- First posted
- Jun 9, 2022
- Last posted
- Jul 21, 2022
- Enrollment
- 130
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AIDS Malignancy ConsortiumLead sponsor
- National Cancer Institute (NCI)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.